Janssen-Cilag discontinues Comfyde for epilepsy
This article was originally published in Scrip
Janssen-Cilag (Johnson & Johnson) has withdrawn an EU marketing application for its troubled anticonvulsant Comfyde (carisbamate) for the treatment of partial onset seizures in patients with epilepsy and discontinued developing it for the treatment of epilepsy.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.